메뉴 건너뛰기




Volumn 5, Issue 3, 2016, Pages 288-300

Non-small cell lung cancer: Current treatment and future advances

Author keywords

Chemotherapy; Immunotherapy; Non small cell lung cancer (NSCLC)

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BELAGENPUMATUCEL L; BIOLOGICAL MARKER; CANCER VACCINE; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; IPILIMUMAB; MELANOMA ANTIGEN 3; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TECEMOTIDE; TG 4010;

EID: 84977470126     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.21037/tlcr.2016.06.07     Document Type: Article
Times cited : (1385)

References (106)
  • 2
    • 84958842243 scopus 로고    scopus 로고
    • American Cancer Society. Cancer Facts and Figures 2015. Available online: http://www.cancer.org/acs/groups/ content/@editorial/documents/document/acspc-044552.pdf
    • (2015) Cancer Facts and Figures
  • 3
    • 3543064179 scopus 로고
    • National Cancer Institute. SEER Cancer Statistics Review, 1975-2011. Available online: http://seer.cancer.gov/ csr/1975_2011/
    • (1975) SEER Cancer Statistics Review
  • 5
    • 45349086437 scopus 로고    scopus 로고
    • Comparison of aspects of smoking among the four histological types of lung cancer
    • Kenfield SA, Wei EK, Stampfer MJ, et al. Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 2008;17:198-204.
    • (2008) Tob Control , vol.17 , pp. 198-204
    • Kenfield, S.A.1    Wei, E.K.2    Stampfer, M.J.3
  • 7
    • 84861336752 scopus 로고    scopus 로고
    • Lung cancer in never smokers--a review
    • Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokers--a review. Eur J Cancer 2012;48:1299-311.
    • (2012) Eur J Cancer , vol.48 , pp. 1299-1311
    • Couraud, S.1    Zalcman, G.2    Milleron, B.3
  • 9
    • 0031193898 scopus 로고    scopus 로고
    • Impact of filter cigarette smoking on lung cancer histology
    • Stellman SD, Muscat JE, Hoffmann D, et al. Impact of filter cigarette smoking on lung cancer histology. Prev Med 1997;26:451-6.
    • (1997) Prev Med , vol.26 , pp. 451-456
    • Stellman, S.D.1    Muscat, J.E.2    Hoffmann, D.3
  • 10
    • 84977510730 scopus 로고    scopus 로고
    • Large cell carcinoma. In: Travis W, Brambilla E, Müller-Hermelink H, et al. editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. WHO Press, Geneva, 2004:45-50.
    • Brambilla E, Pugatch B, Geisinger K, et al. Large cell carcinoma. In: Travis W, Brambilla E, Müller-Hermelink H, et al. editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. WHO Press, Geneva, 2004:45-50.
    • Brambilla, E.1    Pugatch, B.2    Geisinger, K.3
  • 12
    • 0033591845 scopus 로고    scopus 로고
    • Tobacco smoke carcinogens and lung cancer
    • Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
    • (1999) J Natl Cancer Inst , vol.91 , pp. 1194-1210
    • Hecht, S.S.1
  • 13
    • 0346888299 scopus 로고    scopus 로고
    • Environmental exposure to carcinogens causing lung cancer: epidemiological evidence from the medical literature
    • Whitrow MJ, Smith BJ, Pilotto LS, et al. Environmental exposure to carcinogens causing lung cancer: epidemiological evidence from the medical literature. Respirology 2003;8:513-21.
    • (2003) Respirology , vol.8 , pp. 513-521
    • Whitrow, M.J.1    Smith, B.J.2    Pilotto, L.S.3
  • 14
    • 84893235639 scopus 로고    scopus 로고
    • The Health Consequences of Smoking-50 Years of Progress
    • A Report of the Surgeon General
    • U.S. Dept. of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General, 2014. Available online: http:// www.surgeongeneral.gov/library/reports/50-years-ofprogress/
    • (2014)
  • 15
    • 84977584340 scopus 로고    scopus 로고
    • United States Environmental Protection Agency. Health Risk of Radon. Available online: https://www.epa.gov/ radon/health-risk-radon
    • Health Risk of Radon
  • 16
    • 20044393174 scopus 로고    scopus 로고
    • Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies
    • Krewski D, Lubin JH, Zielinski JM, et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 2005;16:137-45.
    • (2005) Epidemiology , vol.16 , pp. 137-145
    • Krewski, D.1    Lubin, J.H.2    Zielinski, J.M.3
  • 17
    • 33645950743 scopus 로고    scopus 로고
    • A combined analysis of North American case-control studies of residential radon and lung cancer
    • Krewski D, Lubin JH, Zielinski JM, et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A 2006;69:533-97.
    • (2006) J Toxicol Environ Health A , vol.69 , pp. 533-597
    • Krewski, D.1    Lubin, J.H.2    Zielinski, J.M.3
  • 18
    • 19944430921 scopus 로고    scopus 로고
    • Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies
    • Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 2005;330:223.
    • (2005) BMJ , vol.330 , pp. 223
    • Darby, S.1    Hill, D.2    Auvinen, A.3
  • 19
    • 0034554756 scopus 로고    scopus 로고
    • The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure
    • Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000;44:565-601.
    • (2000) Ann Occup Hyg , vol.44 , pp. 565-601
    • Hodgson, J.T.1    Darnton, A.2
  • 20
    • 49449108502 scopus 로고    scopus 로고
    • A meta-analysis of asbestosrelated cancer risk that addresses fiber size and mineral type
    • Berman DW, Crump KS. A meta-analysis of asbestosrelated cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol 2008;38 Suppl 1:49-73.
    • (2008) Crit Rev Toxicol , Issue.38 , pp. 49-73
    • Berman, D.W.1    Crump, K.S.2
  • 21
    • 50649118149 scopus 로고    scopus 로고
    • An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers
    • Stayner L, Kuempel E, Gilbert S, et al. An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers. Occup Environ Med 2008;65:613-9.
    • (2008) Occup Environ Med , vol.65 , pp. 613-619
    • Stayner, L.1    Kuempel, E.2    Gilbert, S.3
  • 22
    • 0030725131 scopus 로고    scopus 로고
    • Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study
    • van Loon AJ, Kant IJ, Swaen GM, et al. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med 1997;54:817-24.
    • (1997) Occup Environ Med , vol.54 , pp. 817-824
    • van Loon, A.J.1    Kant, I.J.2    Swaen, G.M.3
  • 24
    • 27744471941 scopus 로고    scopus 로고
    • Air pollution and cancer: biomarker studies in human populations
    • Vineis P, Husgafvel-Pursiainen K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 2005;26:1846-55.
    • (2005) Carcinogenesis , vol.26 , pp. 1846-1855
    • Vineis, P.1    Husgafvel-Pursiainen, K.2
  • 25
    • 0037029043 scopus 로고    scopus 로고
    • Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution
    • Pope CA 3rd, Burnett RT, Thun MJ, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 2002;287:1132-41.
    • (2002) JAMA , vol.287 , pp. 1132-1141
    • Pope C.A, 3rd.1    Burnett, R.T.2    Thun, M.J.3
  • 27
    • 0042566080 scopus 로고    scopus 로고
    • Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk
    • Hwang SJ, Cheng LS, Lozano G, et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003;113:238-43.
    • (2003) Hum Genet , vol.113 , pp. 238-243
    • Hwang, S.J.1    Cheng, L.S.2    Lozano, G.3
  • 28
    • 41649103052 scopus 로고    scopus 로고
    • A variant associated with nicotine dependence, lung cancer and peripheral arterial disease
    • Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-42.
    • (2008) Nature , vol.452 , pp. 638-642
    • Thorgeirsson, T.E.1    Geller, F.2    Sulem, P.3
  • 29
    • 41649103682 scopus 로고    scopus 로고
    • A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
    • Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7.
    • (2008) Nature , vol.452 , pp. 633-637
    • Hung, R.J.1    McKay, J.D.2    Gaborieau, V.3
  • 30
    • 42649091460 scopus 로고    scopus 로고
    • Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1
    • Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-22.
    • (2008) Nat Genet , vol.40 , pp. 616-622
    • Amos, C.I.1    Wu, X.2    Broderick, P.3
  • 31
    • 84877669806 scopus 로고    scopus 로고
    • Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    • Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e278S-313S.
    • (2013) Chest , vol.143 , pp. e278S-313S
    • Howington, J.A.1    Blum, M.G.2    Chang, A.C.3
  • 32
    • 84971581087 scopus 로고
    • Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials.
    • Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
    • (1995) BMJ , vol.311 , pp. 899-909
  • 33
    • 42049099094 scopus 로고    scopus 로고
    • Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions
    • Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13 Suppl 1:5-13.
    • (2008) Oncologist , Issue.13 , pp. 5-13
    • Ramalingam, S.1    Belani, C.2
  • 34
    • 84945194223 scopus 로고    scopus 로고
    • Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    • Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3488-515.
    • (2015) J Clin Oncol , vol.33 , pp. 3488-3515
    • Masters, G.A.1    Temin, S.2    Azzoli, C.G.3
  • 35
    • 0035397994 scopus 로고    scopus 로고
    • Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial
    • Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
    • (2001) J Clin Oncol , vol.19 , pp. 3210-3218
    • Kelly, K.1    Crowley, J.2    Bunn P.A, Jr.3
  • 36
    • 0036843105 scopus 로고    scopus 로고
    • Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    • Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91.
    • (2002) J Clin Oncol , vol.20 , pp. 4285-4291
    • Scagliotti, G.V.1    De Marinis, F.2    Rinaldi, M.3
  • 37
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer
    • Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002;346:92-8.
    • (2002) N Engl J Med , vol.346 , pp. 92-98
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3
  • 38
    • 0042413836 scopus 로고    scopus 로고
    • Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
    • Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24.
    • (2003) J Clin Oncol , vol.21 , pp. 3016-3024
    • Fossella, F.1    Pereira, J.R.2    von Pawel, J.3
  • 39
    • 11144357752 scopus 로고    scopus 로고
    • Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
    • Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004;15:419-26.
    • (2004) Ann Oncol , vol.15 , pp. 419-426
    • Gridelli, C.1    Ardizzoni, A.2    Le Chevalier, T.3
  • 40
    • 36849080232 scopus 로고    scopus 로고
    • Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline
    • Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-18.
    • (2007) J Clin Oncol , vol.25 , pp. 5506-5518
    • Pisters, K.M.1    Evans, W.K.2    Azzoli, C.G.3
  • 41
    • 34848866332 scopus 로고    scopus 로고
    • Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition)
    • Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:234S-242S.
    • (2007) Chest , vol.132 , pp. 234S-242S
    • Scott, W.J.1    Howington, J.2    Feigenberg, S.3
  • 42
    • 84907914142 scopus 로고    scopus 로고
    • Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review
    • Amini A, Yeh N, Gaspar LE, et al. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol 2014;9:210.
    • (2014) Radiat Oncol , vol.9 , pp. 210
    • Amini, A.1    Yeh, N.2    Gaspar, L.E.3
  • 43
    • 77950312339 scopus 로고    scopus 로고
    • Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis
    • Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010;95:32-40.
    • (2010) Radiother Oncol , vol.95 , pp. 32-40
    • Grutters, J.P.1    Kessels, A.G.2    Pijls-Johannesma, M.3
  • 44
    • 68049136288 scopus 로고    scopus 로고
    • Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study
    • Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-82.
    • (2009) Int J Radiat Oncol Biol Phys , vol.75 , pp. 677-682
    • Fakiris, A.J.1    McGarry, R.C.2    Yiannoutsos, C.T.3
  • 45
    • 77949520655 scopus 로고    scopus 로고
    • Stereotactic body radiation therapy for inoperable early stage lung cancer
    • Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6.
    • (2010) JAMA , vol.303 , pp. 1070-1076
    • Timmerman, R.1    Paulus, R.2    Galvin, J.3
  • 46
    • 84859843601 scopus 로고    scopus 로고
    • Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer
    • Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83:348-53.
    • (2012) Int J Radiat Oncol Biol Phys , vol.83 , pp. 348-353
    • Lagerwaard, F.J.1    Verstegen, N.E.2    Haasbeek, C.J.3
  • 47
    • 81855203431 scopus 로고    scopus 로고
    • Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
    • Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011;81:1352-8.
    • (2011) Int J Radiat Oncol Biol Phys , vol.81 , pp. 1352-1358
    • Onishi, H.1    Shirato, H.2    Nagata, Y.3
  • 48
    • 65349107082 scopus 로고    scopus 로고
    • KRAS mutations in non-small cell lung cancer
    • Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5.
    • (2009) Proc Am Thorac Soc , vol.6 , pp. 201-205
    • Riely, G.J.1    Marks, J.2    Pao, W.3
  • 49
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 50
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    • Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Jänne, P.A.2    Lee, J.C.3
  • 51
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3
  • 52
    • 55949122976 scopus 로고    scopus 로고
    • KRAS mutations: an old oncogene becomes a new predictive biomarker
    • Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 2008;10:493-5.
    • (2008) J Mol Diagn , vol.10 , pp. 493-495
    • Riely, G.J.1    Ladanyi, M.2
  • 53
    • 53249145767 scopus 로고    scopus 로고
    • Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    • Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-4.
    • (2008) Clin Cancer Res , vol.14 , pp. 5731-5734
    • Riely, G.J.1    Kris, M.G.2    Rosenbaum, D.3
  • 54
    • 0036894746 scopus 로고    scopus 로고
    • BRAF and RAS mutations in human lung cancer and melanoma
    • Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
    • (2002) Cancer Res , vol.62 , pp. 6997-7000
    • Brose, M.S.1    Volpe, P.2    Feldman, M.3
  • 55
    • 84888639050 scopus 로고    scopus 로고
    • K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
    • Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-51.
    • (2013) Nature , vol.503 , pp. 548-551
    • Ostrem, J.M.1    Peters, U.2    Sos, M.L.3
  • 56
    • 34547638047 scopus 로고    scopus 로고
    • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    • Nature
    • Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
    • (2007) , vol.448 , pp. 561-566
    • Soda, M.1    Choi, Y.L.2    Enomoto, M.3
  • 57
    • 57349113565 scopus 로고    scopus 로고
    • Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
    • Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24.
    • (2008) Clin Cancer Res , vol.14 , pp. 6618-6624
    • Takeuchi, K.1    Choi, Y.L.2    Soda, M.3
  • 58
    • 48249114422 scopus 로고    scopus 로고
    • EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
    • Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83.
    • (2008) Clin Cancer Res , vol.14 , pp. 4275-4283
    • Koivunen, J.P.1    Mermel, C.2    Zejnullahu, K.3
  • 59
    • 79955482290 scopus 로고    scopus 로고
    • Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors
    • Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 2011;6:905-12.
    • (2011) J Thorac Oncol , vol.6 , pp. 905-912
    • Koh, Y.1    Kim, D.W.2    Kim, T.M.3
  • 60
    • 37549060017 scopus 로고    scopus 로고
    • EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
    • Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-7.
    • (2008) J Thorac Oncol , vol.3 , pp. 13-17
    • Inamura, K.1    Takeuchi, K.2    Togashi, Y.3
  • 61
    • 63949087355 scopus 로고    scopus 로고
    • EML4-ALK lung cancers are characterized by rare other mutations, a TTF- 1 cell lineage, an acinar histology, and young onset
    • Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF- 1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-15.
    • (2009) Mod Pathol , vol.22 , pp. 508-515
    • Inamura, K.1    Takeuchi, K.2    Togashi, Y.3
  • 62
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
    • (2010) N Engl J Med , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 63
    • 84856695102 scopus 로고    scopus 로고
    • KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only
    • Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7:e31323.
    • (2012) PLoS One , vol.7 , pp. e31323
    • Togashi, Y.1    Soda, M.2    Sakata, S.3
  • 64
    • 84918804764 scopus 로고    scopus 로고
    • First-line crizotinib versus chemotherapy in ALK-positive lung cancer
    • Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
    • (2014) N Engl J Med , vol.371 , pp. 2167-2177
    • Solomon, B.J.1    Mok, T.2    Kim, D.W.3
  • 66
    • 84883022821 scopus 로고    scopus 로고
    • Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer
    • Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19:4532-40.
    • (2013) Clin Cancer Res , vol.19 , pp. 4532-4540
    • Cardarella, S.1    Ogino, A.2    Nishino, M.3
  • 67
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
    • (2002) Nature , vol.417 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3
  • 68
    • 0036895599 scopus 로고    scopus 로고
    • Missense mutations of the BRAF gene in human lung adenocarcinoma
    • Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-3.
    • (2002) Cancer Res , vol.62 , pp. 7001-7003
    • Naoki, K.1    Chen, T.H.2    Richards, W.G.3
  • 69
    • 79956316170 scopus 로고    scopus 로고
    • Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations
    • Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-51.
    • (2011) J Clin Oncol , vol.29 , pp. 2046-2051
    • Paik, P.K.1    Arcila, M.E.2    Fara, M.3
  • 70
    • 55949097252 scopus 로고    scopus 로고
    • Genetic predictors of MEK dependence in non-small cell lung cancer
    • Pratilas CA, Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008;68:9375-83.
    • (2008) Cancer Res , vol.68 , pp. 9375-9383
    • Pratilas, C.A.1    Hanrahan, A.J.2    Halilovic, E.3
  • 71
    • 79953151458 scopus 로고    scopus 로고
    • Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
    • Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
    • (2011) Science , vol.331 , pp. 1565-1570
    • Schreiber, R.D.1    Old, L.J.2    Smyth, M.J.3
  • 72
    • 0032546352 scopus 로고    scopus 로고
    • Dendritic cells and the control of immunity
    • Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
    • (1998) Nature , vol.392 , pp. 245-252
    • Banchereau, J.1    Steinman, R.M.2
  • 73
    • 52449102477 scopus 로고    scopus 로고
    • Longterm survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures
    • Dieu-Nosjean MC, Antoine M, Danel C, et al. Longterm survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-7.
    • (2008) J Clin Oncol , vol.26 , pp. 4410-4417
    • Dieu-Nosjean, M.C.1    Antoine, M.2    Danel, C.3
  • 74
    • 76149124214 scopus 로고    scopus 로고
    • A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis
    • Zhuang X, Xia X, Wang C, et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010;18:24-8.
    • (2010) Appl Immunohistochem Mol Morphol , vol.18 , pp. 24-28
    • Zhuang, X.1    Xia, X.2    Wang, C.3
  • 75
    • 0036136050 scopus 로고    scopus 로고
    • Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer
    • Villegas FR, Coca S, Villarrubia VG, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002;35:23-8.
    • (2002) Lung Cancer , vol.35 , pp. 23-28
    • Villegas, F.R.1    Coca, S.2    Villarrubia, V.G.3
  • 76
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 77
    • 84863911486 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
    • Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54.
    • (2012) J Clin Oncol , vol.30 , pp. 2046-2054
    • Lynch, T.J.1    Bondarenko, I.2    Luft, A.3
  • 78
    • 84966405086 scopus 로고    scopus 로고
    • FDA Approval Summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy
    • Kazandjian D, Suzman DL, Blumenthal G, et al. FDA Approval Summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 2016;21:634-42.
    • (2016) Oncologist , vol.21 , pp. 634-642
    • Kazandjian, D.1    Suzman, D.L.2    Blumenthal, G.3
  • 79
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
    • (2015) N Engl J Med , vol.373 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3
  • 80
    • 84977543761 scopus 로고    scopus 로고
    • A phase 3 study of opdivo (nivolumab) compared to docetaxel in patients with second-line squamous cell non-small cell lung cancer, stopped early
    • Brystol-Myers Squibb. CheckMate-017, A phase 3 study of opdivo (nivolumab) compared to docetaxel in patients with second-line squamous cell non-small cell lung cancer, stopped early. Available online: http://news.bms.com/pressrelease/ checkmate-017-phase-3-study-opdivo-nivolumabcompared-docetaxel-patients-second-line-s
    • CheckMate-017
    • Squibb, B.-M.1
  • 81
    • 84907614647 scopus 로고    scopus 로고
    • Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)
    • Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Pro 2014;32:8007.
    • (2014) ASCO Annual Meeting Pro , vol.32 , pp. 8007
    • Rizvi, N.A.1    Garon, E.B.2    Patnaik, A.3
  • 82
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 83
    • 84869787349 scopus 로고    scopus 로고
    • Immunotherapies: the blockade of inhibitory signals
    • Wu YL, Liang J, Zhang W, et al. Immunotherapies: the blockade of inhibitory signals. Int J Biol Sci 2012;8:1420-30.
    • (2012) Int J Biol Sci , vol.8 , pp. 1420-1430
    • Wu, Y.L.1    Liang, J.2    Zhang, W.3
  • 84
    • 0038153907 scopus 로고    scopus 로고
    • Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma
    • Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 8372-8377
    • Phan, G.Q.1    Yang, J.C.2    Sherry, R.M.3
  • 85
    • 84859158384 scopus 로고    scopus 로고
    • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    • Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12.
    • (2012) Curr Opin Immunol , vol.24 , pp. 207-212
    • Topalian, S.L.1    Drake, C.G.2    Pardoll, D.M.3
  • 86
    • 34547794178 scopus 로고    scopus 로고
    • PD-1 and PD-1 ligands: from discovery to clinical application
    • Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813-24.
    • (2007) Int Immunol , vol.19 , pp. 813-824
    • Okazaki, T.1    Honjo, T.2
  • 87
    • 0035874949 scopus 로고    scopus 로고
    • Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
    • Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
    • (2001) Cancer Res , vol.61 , pp. 4766-4772
    • Woo, E.Y.1    Chu, C.S.2    Goletz, T.J.3
  • 88
    • 0036569127 scopus 로고    scopus 로고
    • Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation
    • Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
    • (2002) J Immunol , vol.168 , pp. 4272-4276
    • Woo, E.Y.1    Yeh, H.2    Chu, C.S.3
  • 89
    • 33750586798 scopus 로고    scopus 로고
    • Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
    • Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-30.
    • (2006) J Clin Oncol , vol.24 , pp. 4721-4730
    • Nemunaitis, J.1    Dillman, R.O.2    Schwarzenberger, P.O.3
  • 90
    • 84943665476 scopus 로고    scopus 로고
    • A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
    • Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer 2015;51:2321-9.
    • (2015) Eur J Cancer , vol.51 , pp. 2321-2329
    • Giaccone, G.1    Bazhenova, L.A.2    Nemunaitis, J.3
  • 91
    • 42549106307 scopus 로고    scopus 로고
    • Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
    • Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). ASCO Annual Meeting Pro 2007;25:7554.
    • (2007) ASCO Annual Meeting Pro , vol.25 , pp. 7554
    • Vansteenkiste, J.1    Zielinski, M.2    Linder, A.3
  • 92
    • 77249089345 scopus 로고    scopus 로고
    • MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy
    • Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-4.
    • (2009) Clin Lung Cancer , vol.10 , pp. 371-374
    • Tyagi, P.1    Mirakhur, B.2
  • 93
    • 27244449289 scopus 로고    scopus 로고
    • Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer
    • Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81.
    • (2005) J Clin Oncol , vol.23 , pp. 6674-6681
    • Butts, C.1    Murray, N.2    Maksymiuk, A.3
  • 94
    • 80054742888 scopus 로고    scopus 로고
    • Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
    • Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137:1337-42.
    • (2011) J Cancer Res Clin Oncol , vol.137 , pp. 1337-1342
    • Butts, C.1    Maksymiuk, A.2    Goss, G.3
  • 95
    • 84891373760 scopus 로고    scopus 로고
    • Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
    • Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
    • (2014) Lancet Oncol , vol.15 , pp. 59-68
    • Butts, C.1    Socinski, M.A.2    Mitchell, P.L.3
  • 96
    • 41149159650 scopus 로고    scopus 로고
    • Osorio Rodríguez M, Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-smallcell lung cancer
    • Neninger Vinageras E, de la Torre A, et al. Osorio Rodríguez M, Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-smallcell lung cancer. J Clin Oncol 2008;26:1452-8.
    • (2008) J Clin Oncol , vol.26 , pp. 1452-1458
    • Neninger Vinageras, E.1    de la Torre, A.2
  • 97
    • 50349090322 scopus 로고    scopus 로고
    • A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer
    • Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008;3:735-44.
    • (2008) J Thorac Oncol , vol.3 , pp. 735-744
    • Ramlau, R.1    Quoix, E.2    Rolski, J.3
  • 98
    • 81255127285 scopus 로고    scopus 로고
    • Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
    • Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12:1125-33.
    • (2011) Lancet Oncol , vol.12 , pp. 1125-1133
    • Quoix, E.1    Ramlau, R.2    Westeel, V.3
  • 99
    • 48149104076 scopus 로고    scopus 로고
    • Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
    • de Gruijl TD, van den Eertwegh AJ, Pinedo HM, et al. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008;57:1569-77.
    • (2008) Cancer Immunol Immunother , vol.57 , pp. 1569-1577
    • de Gruijl, T.D.1    van den Eertwegh, A.J.2    Pinedo, H.M.3
  • 100
    • 84880099830 scopus 로고    scopus 로고
    • Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies
    • Iyengar P, Gerber DE. Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J 2013;19:247-62.
    • (2013) Cancer J , vol.19 , pp. 247-262
    • Iyengar, P.1    Gerber, D.E.2
  • 101
    • 0022617915 scopus 로고
    • Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness
    • Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136:3916-20.
    • (1986) J Immunol , vol.136 , pp. 3916-3920
    • Rook, A.H.1    Kehrl, J.H.2    Wakefield, L.M.3
  • 102
    • 0033229730 scopus 로고    scopus 로고
    • Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma
    • Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712-9.
    • (1999) Cancer , vol.86 , pp. 1712-1719
    • Kong, F.1    Jirtle, R.L.2    Huang, D.H.3
  • 103
    • 0025963594 scopus 로고
    • Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
    • Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-30.
    • (1991) J Exp Med , vol.173 , pp. 721-730
    • Linsley, P.S.1    Brady, W.2    Grosmaire, L.3
  • 104
    • 1142286444 scopus 로고    scopus 로고
    • MUC1 immunobiology: from discovery to clinical applications
    • Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93.
    • (2004) Adv Immunol , vol.82 , pp. 249-293
    • Vlad, A.M.1    Kettel, J.C.2    Alajez, N.M.3
  • 105
    • 12244304887 scopus 로고    scopus 로고
    • Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
    • Gonzalez G, Crombet T, Torres F, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14:461-6.
    • (2003) Ann Oncol , vol.14 , pp. 461-466
    • Gonzalez, G.1    Crombet, T.2    Torres, F.3
  • 106
    • 0034766337 scopus 로고    scopus 로고
    • Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2
    • Trevor KT, Hersh EM, Brailey J, et al. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother 2001;50:397-407.
    • (2001) Cancer Immunol Immunother , vol.50 , pp. 397-407
    • Trevor, K.T.1    Hersh, E.M.2    Brailey, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.